Dr. Ray's research focuses on innovative nanodiagnostics, with a long term interest in hepatitis C virus (HCV) sequence evolution and persistence. HCV affects more than 3 million people in the United States and nearly 200 million worldwide. Current treatment is highly effective but expensive, and most infected people are unaware of their infection. Thus, Dr. Ray remains dedicated to enhanced screening, access to care, and rational vaccine development for HCV.
Technology Expertise Keywords
nanodiagnostics; computational biology; virology; immunology
View all on Pubmed
Wasilewski LN, El-Diwany R, Munshaw S, Snider AE, Brady JK, Osburn WO, Ray SC, Bailey JR. A Hepatitis C Virus Envelope Polymorphism Confers Resistance to Neutralization by Polyclonal Sera and Broadly Neutralizing Monoclonal Antibodies. Journal of Virology. 2016; 90(7):3773-82.
Bailey JR, Dowd KA, Snider AE, Osburn WO, Mehta SH, Kirk GD, Thomas DL, Ray SC. CD4+ T-Cell-Dependent Reduction in Hepatitis C Virus-Specific Neutralizing Antibody Responses After Coinfection With Human Immunodeficiency Virus. The Journal of Infectious Diseases. 2015; 212(6):914-23.
El-Diwany R, Wasilewski LN, Witwer KW, Bailey JR, Page K, Ray SC, Cox AL, Thomas DL, Balagopal A. Acute Hepatitis C Virus Infection Induces Consistent Changes in Circulating MicroRNAs That Are Associated with Nonlytic Hepatocyte Release. Journal of Virology. 2015; 89(18):9454-64.
Newman RM, Lamers SL, Weiner B, Ray SC, Colgrove RC, Diaz F, Jing L, Wang K, Saif S, Young S, Henn M, Laeyendecker O, Tobian AA, Cohen JI, Koelle DM, Quinn TC, Knipe DM. Genome Sequencing and Analysis of Lamers SL, Newman RM, Laeyendecker O, Tobian AA, Colgrove RC, Ray SC, Koelle DM, Cohen J, Knipe DM, Quinn TC. Geographically Diverse Clinical Isolates of Herpes Simplex Virus 2. Journal of Virology. 2015; 89(16):8219-32.
Global Diversity within and between Human Herpesvirus 1 and 2 Glycoproteins. Journal of Virology. 2015; 89(16):8206-18.
Bailey JR, Wasilewski LN, Snider AE, El-Diwany R, Osburn WO, Keck Z, Foung SK, Ray SC. Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance. The Journal of Clinical Iinvestigation. 2015; 125(1):437-47.
Graw F, Balagopal A, Kandathil AJ, Ray SC, Thomas DL, Ribeiro RM, Perelson AS. Inferring viral dynamics in chronically HCV infected patients from the spatial distribution of infected hepatocytes. PLoS Computational Biology. 2014; 10(11):e1003934.
Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
Patent # USPTO 8168771 | 05/01/2012
Synthetic hepatitis C genome and methods of making and use
Patent # USPTO 9512183
Synthetic representative HCV subtypes, including a 1a and 1b genome, dubbed Bole1a and Bole1b, are provided using an inventive method of Bayesian phylogenetic tree analysis, ancestral sequence reconstruction and covariance analysis. Bole1a branches centrally among 390 full-genome sequences used in its design, a carefully curated 143 sequence full-genome dataset, and separate genomic regions including an independent set of 214 E1E2 sequences from a Baltimore cohort. Bole1a is phylogenetically representative of widely circulating strains. Full genome non-synonymous diversity comparison and 9-mer peptide coverage analysis showed that Bole1a is able to provide more coverage (94% and 78% respectively) than any other sequence in the dataset including H77, a traditional reference sequence. Bole1a also provides unsurpassed epitope coverage when compared to all known T cell epitopes.